Welcome to our dedicated page for RECURSION PHARMACEUTICALS SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
HERSHBERG ROBERT reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Robert Hershberg received an equity grant of 88,424 shares of Class A Common Stock in the form of restricted stock units. The grant was made at no cash cost under the company’s Outside Director Compensation Policy as a routine award.
These restricted stock units vest on the earlier of June 17, 2027 or the day before the company’s 2027 annual stockholder meeting, contingent on his continued service. Following this grant, Hershberg directly holds 162,156 shares reported as beneficially owned.
Michor Franziska reported acquisition or exercise transactions in this Form 4 filing.
Recursion Pharmaceuticals director Franziska Michor received a grant of 88,424 restricted stock units of Class A Common Stock as compensation under the company’s Outside Director Compensation Policy. The units were granted at $0.00 per share, reflecting a stock-based award rather than an open-market purchase.
The restricted stock units will vest on the earlier of June 17, 2027 or the day prior to Recursion’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, Michor directly holds 215,477 shares of the company’s Class A Common Stock.
Sun Elaine D reported acquisition or exercise transactions in this Form 4 filing.
Recursion Pharmaceuticals director Elaine D. Sun received an equity award of 88,424 shares of Class A Common Stock in the form of restricted stock units. The award was granted at no cash cost to her under the company’s Outside Director Compensation Policy.
The restricted stock units will vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 Annual Meeting of Stockholders, provided she continues serving the company. Following this grant, Sun directly holds 135,981 shares of Class A Common Stock.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS director Zavain Dar received an equity grant. He was awarded 88,424 shares of Class A Common Stock in the form of restricted stock units for board service, at no cash cost. These RSUs vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholder meeting, subject to continued service, bringing his direct holdings to 235,655 shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li reported an equity award and updated holdings in Class A Common Stock. He received a grant of 88,424 restricted stock units, automatically granted under the company’s Outside Director Compensation Policy, at a stated price of $0.00 per share.
The restricted stock units will vest on the earlier of June 17, 2027 or the day prior to the company’s 2027 Annual Meeting of Stockholders, as long as he continues to serve the company. Following this award, Li holds 1,469,582 shares directly, plus indirect holdings through the Dean Y. Li 2021 Family Trust and the Dean Y. Li Revocable Trust.
RECURSION PHARMACEUTICALS, INC. director Namandje Bumpus reported both an equity award and a small share sale. On June 17, 2026, Bumpus received a grant of 88,424 restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholders’ meeting, subject to continued service.
On June 18, 2026, Bumpus sold 3,963 shares of Class A Common Stock in an open‑market transaction at $3.18 per share, executed under a Rule 10b5‑1 trading plan adopted on March 3, 2026. After the reported transactions, Bumpus directly owned 127,632 shares of Class A Common Stock.
Recursion Pharmaceuticals, Inc. reported the results of its 2026 annual stockholder meeting held on June 17, 2026. Stockholders elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., to serve until the 2029 annual meeting or until successors are elected and qualified.
Stockholders also approved, on an advisory basis, the Company’s executive compensation, with 206,171,008 votes for, 30,893,147 against, and 1,280,852 abstentions, plus 126,675,762 broker non-votes. In addition, they ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 361,743,500 votes for, 2,148,771 against, and 1,128,498 abstentions.
Christopher C. Gibson reported sales of Class A shares under Rule 144. The filing lists six open-market dispositions of 40,000 shares each on 03/23/2026, 04/07/2026, 04/22/2026, 05/07/2026, 05/22/2026, and 06/05/2026, with aggregate proceeds shown per transaction. The filing also lists scheduled Restricted Stock Vesting events for Class A shares on multiple dates in 2025–2026 with individual vesting amounts disclosed.
RXRX affiliate submitted a Form 144 reporting proposed sales of Class A shares tied to restricted stock vesting. The filing lists 3,963 Class A shares with an effective date of 06/18/2026 described as Restricted Stock Vesting for compensation. The filing also shows 4,386 Class A shares sold on 06/03/2026 by Namandje Bumpus.
RXRX reported proposed sales of Class A shares under Form 144. The filing lists multiple 40,000-share entries with trade dates between 03/23/2026 and 06/05/2026, each showing a dollar value tied to the block (for example, $130,000 on 03/23/2026). The filing identifies these as Founders Shares and lists Fidelity Brokerage Services LLC as a broker.